(UroToday.com) At the 2020 European Society for Medical Oncology Virtual Congress (ESMO), Dr. Ben Tran presented AMG 160, a half-life extended, PSMA-targeted, bispecific T-cell engager (BiTE®) for patients with metastatic castration-resistant prostate cancer (mCRPC) (NCT03792841). Dr. Cora Sternberg then provided the invited discussant presentation of this new research in prostate immunotherapy.